Deinove S.A. (ALDEI.PA)
Deinove S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Grabels, FR. The stock last traded at $0.03, up 0.00% on the session, giving a market capitalisation of $1.1M. Its beta of 0.79 implies it has historically moved less than the broad market.
Headquartered in Grabels, France, DEINOVE SA is a biotechnology company founded in 2006. The company focuses on the discovery, development, and production of innovative compounds derived from microorganisms, catering to the global health, nutrition, and cosmetics industries. Among its key developments is DNV3837, an antibiotic currently undergoing Phase II clinical trials for the treatment of Clostridioides difficile infections. In the cosmetics sector, DEINOVE offers a portfolio of specialized ingredients: PHYT-N-Resist, an anti-aging active; Luminity, a carotenoid-based component known for its blue light absorption and potent antioxidant properties; HEBELYS, a natural active ingredient produced through the fermentation of Sphingomonas; and BIOME Oléoactif, a post-biotic extract that provides a prebiotic effect to balance skin microbiota. Beyond these, the company is also advancing a process for creating natural ingredients intended for animal feed. DEINOVE SA maintains strategic alliances with numerous partners, including bioMérieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Oléos-Hallstar, Greentech, and Avril.
Deinove S.A. is most often compared with the following Healthcare names: